Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | MTTP | P55157 | 7/20 | 0.49 |
| ▸ | APOB | P04114 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794893 | 0.85 | POLB (0.53) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6792071 | 0.83 | TRPV1 (0.78) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6789589 | 0.81 | TRPV1 (0.51) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6794545 | 0.80 | TRPV1 (0.60) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6795327 | 0.80 | TRPV1 (0.52) | TRPV1SMOMTTPAPOB | |
| SCHEMBL6794114 | 0.80 | TRPV1 (0.52) | TRPV1SMOMTTPAPOB | |
| SCHEMBL6793244 | 0.80 | SMO (0.62) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6799166 | 0.79 | CHRNB2 (0.59) | TRPV1SMOMTTPAPOBALDH1A1 | |
| SCHEMBL6801569 | 0.79 | TRPV1 (0.68) | TRPV1SMOMTTPAPOBSMN1; SMN2 | |
| SCHEMBL6795000 | 0.79 | MTTP (0.54) | MTTPAPOBALDH1A1PTGS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TRPV1 3714/4885SMO 2094/4885MTTP 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.